AlphaSyn

The AlphaSyn project is developing new and effective small-molecule inhibitors of the neurotoxic aggregation of the protein α-synuclein (αSyn). These inhibitors are discovered via screening of (1) large combinatorial libraries of short cyclic peptides and (2) natural product libraries from Greek marine organisms. The most effective inhibitors of αSyn aggregation and neurotoxicity will be developed with the ultimate goal of developing lead compounds with potentially therapeutic properties against Parkinson’s disease and, in addition, an innovative neuroprotective nutritional supplement promoting the kinetic and cognitive function of elderly people.